ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer

Sara A. Hurvitz | ASCO 2019 | 2. Juni 2019

Speaker: Sara A. Hurvitz

This study is the first dedicated trial of endocrine therapy (ET) ± a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in premenopausal patients (pts) with hormone receptor–positive (HR+)/HER2− ABC. Hear Sara A. Hurvitz present for the first time that a CDK4/6 inhibitor or any targeted agent + endocrine therapi ET has demonstrated significantly longer OS vs ET alone as initial endocrine-based therapy.